CD8A and neoplasm: Mice that rejected large B78 tumors following CRI were rechallenged with B78 tumor cells and received either anti-CD4 mAb, anti-CD8 mAb, a mixture of anti-CD4/anti-CD8 mAb, anti-NK1.1 mAb or control rat IgG.